Payload ID	PAY0ZVBAI
Name	Active metabolite of irinotecan SN38
Synonyms	Active metabolite of irinotecan SN38    Click to Show/Hide
Target	DNA topoisomerase 1 (TOP1)					Target Info
Structure
	3D MOL			2D MOL
Formula	C22H20N2O5
Isosmiles	CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC
InChI	InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3
InChIKey	FJHBVJOVLFPMQE-UHFFFAOYSA-N
Pharmaceutical Properties	Molecule Weight		392.411	Polar area		101.65
	Complexity		29	xlogp Value		2.3476
	Heavy Count		29	Rot Bonds		2
	Hbond acc		7	Hbond Donor		2

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half Maximal Inhibitory Concentration (IC50)	0.13	nM	Daudi cells	Burkitt lymphoma	CVCL_0008	[1]
Half Maximal Inhibitory Concentration (IC50)	0.4	nM	Ramos cells	Burkitt lymphoma	CVCL_0597	[1]
Half Maximal Inhibitory Concentration (IC50)	0.47	nM	Reh cells	B acute lymphoblastic leukemia	CVCL_1650	[1]
Half Maximal Inhibitory Concentration (IC50)	0.5	nM	WSU-FSCCL cells	Follicular lymphoma	CVCL_1903	[1]
Half-maximal effective concentration (EC50)	0.6	nM	Ramos cells	Burkitt lymphoma	CVCL_0597	[1]
Half Maximal Inhibitory Concentration (IC50)	1.2±0.9	nM	DoHH2 cells	Diffuse large B-cell lymphoma germinal center B-cell type	CVCL_1179	[2]
Half Maximal Inhibitory Concentration (IC50)	1.42	nM	Raji cells	EBV-related Burkitt lymphoma	CVCL_0511	[1]
Half-maximal effective concentration (EC50)	1.6	nM	Raji cells	EBV-related Burkitt lymphoma	CVCL_0511	[1]
Half Maximal Inhibitory Concentration (IC50)	123	nM	MN-60 cells	Burkitt lymphoma	CVCL_1421	[1]
Half Maximal Inhibitory Concentration (IC50)	2.23	nM	697 cells	Childhood B acute lymphoblastic leukemia	CVCL_0079	[1]
Half Maximal Inhibitory Concentration (IC50)	2.28	nM	RS4 11 cells	Adult B acute lymphoblastic leukemia	CVCL_0093	[1]
Half Maximal Inhibitory Concentration (IC50)	5±1	nM	Raji cells	EBV-related Burkitt lymphoma	CVCL_0511	[2]
Half Maximal Inhibitory Concentration (IC50)	9±7	nM	Daudi cells	Burkitt lymphoma	CVCL_0008	[2]
Half-maximal effective concentration (EC50)	9.1	nM	Reh cells	B acute lymphoblastic leukemia	CVCL_1650	[1]
Half Maximal Inhibitory Concentration (IC50)	>10	uM	JeKo-1 cells	Mantle cell lymphoma	CVCL_1865	[1]

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	High 5T4 expression (5T4+++)
Method Description	Treated with m603.
In Vivo Model	Pancreatic cancer CDX model
In Vitro Model	Pancreatic cancer	Pancreatic cancer cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 37.83%	High 5T4 expression (5T4+++)
Method Description	Treated with m603-SN38.
In Vivo Model	Pancreatic cancer CDX model
In Vitro Model	Pancreatic cancer	Pancreatic cancer cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.9 nM	High 5T4 expression (5T4+++)
Method Description	Cells in the logarithmic phase of growth were collected and seeded in 96-well plates at a density of 510 3 cells/well and cultured overnight. The culture medium was removed and serial dilution ADCs or naked antibodies were added into the wells of 96-well plates in 200 L medium.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	244.2 nM	Moderate 5T4 expression (5T4++)
Method Description	Cells in the logarithmic phase of growth were collected and seeded in 96-well plates at a density of 510 3 cells/well and cultured overnight. The culture medium was removed and serial dilution ADCs or naked antibodies were added into the wells of 96-well plates in 200 L medium.
In Vitro Model	Adult hepatocellular carcinoma	Huh-7 cells		CVCL_0336

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	High 5T4 expression (5T4+++)
Method Description	Treated with n501.
In Vivo Model	Pancreatic cancer CDX model
In Vitro Model	Pancreatic cancer	Pancreatic cancer cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 62.93%	High 5T4 expression (5T4+++)
Method Description	Treated with n501-SN38.
In Vivo Model	Pancreatic cancer CDX model
In Vitro Model	Pancreatic cancer	Pancreatic cancer cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.9 nM	High 5T4 expression (5T4+++)
Method Description	Cells in the logarithmic phase of growth were collected and seeded in 96-well plates at a density of 510 3 cells/well and cultured overnight. The culture medium was removed and serial dilution ADCs or naked antibodies were added into the wells of 96-well plates in 200 L medium.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	49.8 nM	Moderate 5T4 expression (5T4++)
Method Description	Cells in the logarithmic phase of growth were collected and seeded in 96-well plates at a density of 510 3 cells/well and cultured overnight. The culture medium was removed and serial dilution ADCs or naked antibodies were added into the wells of 96-well plates in 200 L medium.
In Vitro Model	Adult hepatocellular carcinoma	Huh-7 cells		CVCL_0336

Experiment 1 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 22.20%	Positive EDB expression (EDB +++/++)
Method Description	BALB/c nude mice bearing U87MG tumors (450 mm3) were injected intravenously via the tail vein with Abcot (10 mg/kg) or cot-APTEDB-SN38 (equivalent to 2 mg SN38/kg).
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 67%	Positive CD30 expression (CD30+++/++)
Method Description	Tumor cells, as suspensions, were implanted subcutaneously in SCID or nude mice. Upon tumor engraftment, mice were randomized to study groups (5 mice per group) when the average tumor volume reached about 100 mm3. The ADC or vehicle controls were dosed once via intraperitoneal injection. The dose of cAC10-GT=30mg/kg.
In Vivo Model	HD CDX model
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 67%	Positive CD30 expression (CD30+++/++)
Method Description	Tumor cells, as suspensions, were implanted subcutaneously in SCID or nude mice. Upon tumor engraftment, mice were randomized to study groups (5 mice per group) when the average tumor volume reached about 100 mm3. The ADC or vehicle controls were dosed once via intraperitoneal injection. The dose of cAC10-GT=10 mg/kg.
In Vivo Model	HD CDX model
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20 ng/mL	High CD30 expression (CD30+++; 285,000 CD30 molecules/cell)
Method Description	Serial dilutions of ADCs in cell culture media were prepared at 4x working concentrations, and 50 uL of each dilution was added to the 96-well plates. Following addition of test articles, cells were incubated for 4 days at 37°C, after which growth inhibition was assessed by the addition of CellTiter-Glo and luminescence was measured on a plate reader.    Click to Show/Hide
In Vitro Model	Precursor T-cell acute lymphoblastic leukemia	ALCL cells		CVCL_A036
Experiment 4 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	27 ng/mL	High CD30 expression (CD30+++; 180,000 CD30 molecules/cell)
Method Description	Serial dilutions of ADCs in cell culture media were prepared at 4x working concentrations, and 50 uL of each dilution was added to the 96-well plates. Following addition of test articles, cells were incubated for 4 days at 37°C, after which growth inhibition was assessed by the addition of CellTiter-Glo and luminescence was measured on a plate reader.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL/BVR cells		CVCL_1170
Experiment 5 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	79 ng/mL	High CD30 expression (CD30+++; 400,000 CD30 molecules/cell)
Method Description	Serial dilutions of ADCs in cell culture media were prepared at 4x working concentrations, and 50 uL of each dilution was added to the 96-well plates. Following addition of test articles, cells were incubated for 4 days at 37°C, after which growth inhibition was assessed by the addition of CellTiter-Glo and luminescence was measured on a plate reader.    Click to Show/Hide
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	160 ng/mL	High CD30 expression (CD30+++; 320,000 CD30 molecules/cell)
Method Description	Serial dilutions of ADCs in cell culture media were prepared at 4x working concentrations, and 50 uL of each dilution was added to the 96-well plates. Following addition of test articles, cells were incubated for 4 days at 37°C, after which growth inhibition was assessed by the addition of CellTiter-Glo and luminescence was measured on a plate reader.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 7 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	850 ng/mL	Low CD30 expression (CD30+; 70,000 CD30 molecules/cell)
Method Description	Serial dilutions of ADCs in cell culture media were prepared at 4x working concentrations, and 50 uL of each dilution was added to the 96-well plates. Following addition of test articles, cells were incubated for 4 days at 37°C, after which growth inhibition was assessed by the addition of CellTiter-Glo and luminescence was measured on a plate reader.    Click to Show/Hide
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	42 Day	Low CD22 expression (CD22+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.15 mg/dose (2.4 g SN-38 equivalents).
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 2 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	63 Day	Low CD22 expression (CD22+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.30 mg/dose (4.8 g SN-38 equivalents).
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 3 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	140 Day	Low CD22 expression (CD22+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.15 mg/dose (2.4 g SN-38 equivalents) plus Veltuzumab, 35 ug/dose.
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 4 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	> 161 Day	Low CD22 expression (CD22+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.30 mg/dose (4.8 g SN-38 equivalents) plus Veltuzumab, 35 ug/dose.
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903

Experiment 1 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.06 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 2 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.19 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 4 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.34 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 5 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.38 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 6 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.41 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 7 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.46 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 8 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.46 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 9 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 10 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.51 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 11 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.52 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 12 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.68 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 13 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.73 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 14 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.81 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 15 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.83 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 16 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.84 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 17 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.16 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 18 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.16 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 19 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.22 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 20 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.5 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 21 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.66 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 22 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.68 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Adult B acute lymphoblastic leukemia	RS4;11 cells		CVCL_0093
Experiment 23 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.72 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 24 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.77 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 25 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.84 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 26 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	. 2.1 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 27 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.21 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 28 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.25 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 29 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.29 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 30 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.45 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 31 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.67 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Childhood B acute lymphoblastic leukemia	697 cells		CVCL_0079
Experiment 32 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.88 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 33 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.92 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 34 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.65 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	MN-60 cells		CVCL_1421
Experiment 35 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	135.8 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 36 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	152.3 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 37 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	271 nM	High CD20 expression (CD20+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597

Experiment 1 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	63 Day	Low CEACAM5 expression (CEACAM5+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.30 mg/dose (4.8 g SN-38 equivalents).
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 2 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	76 Day	Low CEACAM5 expression (CEACAM5+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.15 mg/dose (2.4 g SN-38 equivalents).
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 3 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	91 Day	Low CEACAM5 expression (CEACAM5+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.30 mg/dose (4.8 g SN-38 equivalents) plus Veltuzumab, 35 ug/dose.
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 4 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	98 Day	Low CEACAM5 expression (CEACAM5+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 106 cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.15 mg/dose (2.4 g SN-38 equivalents) plus Veltuzumab, 35 ug/dose.
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903

Experiment 1 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.17 nM	Low CEACAM5 expression (CEACAM5+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 2 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.73 nM	Low CEACAM5 expression (CEACAM5+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	8.08 nM	Low CEACAM5 expression (CEACAM5+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 4 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 nM	Negative CEACAM5 expression (CEACAM5-)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	MN-60 cells		CVCL_1421
Experiment 5 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 nM	Negative CEACAM5 expression (CEACAM5-)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Adult B acute lymphoblastic leukemia	RS4;11 cells		CVCL_0093
Experiment 6 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 nM	Negative CEACAM5 expression (CEACAM5-)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Childhood B acute lymphoblastic leukemia	697 cells		CVCL_0079
Experiment 7 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 nM	Negative CEACAM5 expression (CEACAM5-)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 8 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 nM	Low CEACAM5 expression (CEACAM5+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 9 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 nM	Negative CEACAM5 expression (CEACAM5-)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597

Experiment 1 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	19 ng/mL	High CD30 expression (CD30+++; 285,000 CD30 molecules/cell)
Method Description	Serial dilutions of ADCs in cell culture media were prepared at 4x working concentrations, and 50 uL of each dilution was added to the 96-well plates. Following addition of test articles, cells were incubated for 4 days at 37°C, after which growth inhibition was assessed by the addition of CellTiter-Glo and luminescence was measured on a plate reader.    Click to Show/Hide
In Vitro Model	Precursor T-cell acute lymphoblastic leukemia	ALCL cells		CVCL_A036
Experiment 2 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	25 ng/mL	High CD30 expression (CD30+++; 180,000 CD30 molecules/cell)
Method Description	Serial dilutions of ADCs in cell culture media were prepared at 4x working concentrations, and 50 uL of each dilution was added to the 96-well plates. Following addition of test articles, cells were incubated for 4 days at 37°C, after which growth inhibition was assessed by the addition of CellTiter-Glo and luminescence was measured on a plate reader.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL/BVR cells		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	46 ng/mL	High CD30 expression (CD30+++; 400,000 CD30 molecules/cell)
Method Description	Serial dilutions of ADCs in cell culture media were prepared at 4x working concentrations, and 50 uL of each dilution was added to the 96-well plates. Following addition of test articles, cells were incubated for 4 days at 37°C, after which growth inhibition was assessed by the addition of CellTiter-Glo and luminescence was measured on a plate reader.    Click to Show/Hide
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	160 ng/mL	High CD30 expression (CD30+++; 320,000 CD30 molecules/cell)
Method Description	Serial dilutions of ADCs in cell culture media were prepared at 4x working concentrations, and 50 uL of each dilution was added to the 96-well plates. Following addition of test articles, cells were incubated for 4 days at 37°C, after which growth inhibition was assessed by the addition of CellTiter-Glo and luminescence was measured on a plate reader.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[5]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	820 ng/mL	Low CD30 expression (CD30+; 70,000 CD30 molecules/cell)
Method Description	Serial dilutions of ADCs in cell culture media were prepared at 4x working concentrations, and 50 uL of each dilution was added to the 96-well plates. Following addition of test articles, cells were incubated for 4 days at 37°C, after which growth inhibition was assessed by the addition of CellTiter-Glo and luminescence was measured on a plate reader.    Click to Show/Hide
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361

Experiment 1 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	14.5 nM	High HER2 expression (HER2+++)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Invasive breast carcinoma	BT474 HerDR cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	157.6 nM	High HER2 expression (HER2+++)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15.9 nM	High HER2 expression (HER2+++)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Invasive breast carcinoma	BT474 HerDR cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	320.8 nM	High HER2 expression (HER2+++)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	484.71 nM	Negative HER2 expression (HER2-)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[8]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	19.71 nM	High EGFR expression (EGFR+++)
Method Description	1 x104 cells per well in a volume of 100 ul were plated in 96-well tissue culture plates. After 24 h, ADCs were added at the indicated concentrations. After 72 h, the medium was removed and the viability was determined using the CellTiter-Glo luminescent cell viability assay kit.
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 2 Reporting the Activity Date of This ADC					[8]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	27.83 nM	High EGFR expression (EGFR+++)
Method Description	1 x104 cells per well in a volume of 100 ul were plated in 96-well tissue culture plates. After 24 h, ADCs were added at the indicated concentrations. After 72 h, the medium was removed and the viability was determined using the CellTiter-Glo luminescent cell viability assay kit.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[8]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	98.81 nM	Moderate EGFR expression (EGFR++)
Method Description	1 x104 cells per well in a volume of 100 ul were plated in 96-well tissue culture plates. After 24 h, ADCs were added at the indicated concentrations. After 72 h, the medium was removed and the viability was determined using the CellTiter-Glo luminescent cell viability assay kit.
In Vitro Model	Invasive breast carcinoma of no special type	BT-20 cells		CVCL_0178
Experiment 4 Reporting the Activity Date of This ADC					[8]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100 nM	Negative EGFR expression (EGFR-)
Method Description	1 x104 cells per well in a volume of 100 ul were plated in 96-well tissue culture plates. After 24 h, ADCs were added at the indicated concentrations. After 72 h, the medium was removed and the viability was determined using the CellTiter-Glo luminescent cell viability assay kit.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	22 nM	High HER2 expression (HER2+++)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Invasive breast carcinoma	BT474 HerDR cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	159.4 nM	High HER2 expression (HER2+++)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	235.6 nM	High HER2 expression (HER2+++)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Invasive breast carcinoma	BT474 HerDR cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	283.8 nM	High HER2 expression (HER2+++)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	SKOV-3, BT474 HerDR, MDA-MB-231 and MCF-7 cells were cultured under various concentrations of Mil40, SN-38 and ADCs for 10days, 9days, 6days, and 6days, respectively. Cytotoxicity assays were established using the CellTiter-Go assay kit (CTG).
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.83 nM	Moderate CD20 expression (CD20++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 2 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.98 nM	High CD20 expression (CD20+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 3 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.88 nM	High CD20 expression (CD20+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	13.56 nM	High CD20 expression (CD20+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 5 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 nM	Low CD20 expression (CD20+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	MN-60 cells		CVCL_1421
Experiment 6 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 nM	Low CD20 expression (CD20+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Adult B acute lymphoblastic leukemia	RS4;11 cells		CVCL_0093
Experiment 7 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 nM	Low CD20 expression (CD20+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Childhood B acute lymphoblastic leukemia	697 cells		CVCL_0079
Experiment 8 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 nM	Low CD20 expression (CD20+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 9 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 50 nM	High CD20 expression (CD20+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 10 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	77.9 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 11 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	162 nM	Low CD20 expression (CD20+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 12 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	246.6 nM	High CD20 expression (CD20+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.7 nM
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.8 nM
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.1 nM
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	77.9 nM	Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	135.8 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	152.3 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597

Experiment 1 Reporting the Activity Date of This ADC					[9]
Efficacy Data	Half Maximal inhibitory Concentration (lC51)	2330 ng/ml
Method Description	The cytotoxicity of ADC against cell lines was evaluated by cell viability test with CellTiter-Glo 2.1 luminescence method.
Experiment 2 Reporting the Activity Date of This ADC					[9]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	244 ng/ml
Method Description	The cytotoxicity of ADC against cell lines was evaluated by cell viability test with CellTiter-Glo 2.0 luminescence method.

Experiment 1 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.112 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were cultured in a 5% CO2 cell incubator at 37°C for 24 hours. Cytotoxicity test contains about 10000 cells when 100uL is added to each well.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.126 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were cultured in a 5% CO2 cell incubator at 37°C for 24 hours. Cytotoxicity test contains about 10000 cells when 101uL is added to each well.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.267 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were cultured in a 5% CO2 cell incubator at 37°C for 24 hours. Cytotoxicity test contains about 10000 cells when 102uL is added to each well.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[11]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.23&#1770.14 nM	High HER2 expression (HER2 +++)
Method Description	The cytotoxicity of Fab-SN38 was evaluated using the Cell Counting Kit-8 (CCK-8) assay. Cells (MDA-MB-231, Calu-3, NCI-N87 and SK-OV-3 cells) were seeded into clear-bottom 96-well plates (~3000 cells per well). After overnight culture, the medium was removed and the fresh medium containing SN38, Glu (SN38)-OH, Glu-SN38, trastuzumab, the Fab protein or the Fab-SN38 conjugate was added and incubated for 72 h at 37 °C in a CO2 incubator. Cell viability was measured using the CCK-8 reagent according to the protocol. Briefly, 15 uL of CCK-8 solution was added to the culture media. Two hours after incubation at 37 °C, the absorbance at a wavelength of 450 nm was measured by a microplate reader (TECAN, Switzerland) and then the IC50 value was profiled using the Graphpad Prism 8 software.    Click to Show/Hide
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 2 Reporting the Activity Date of This ADC					[11]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.5&#1770.16 nM	High HER2 expression (HER2 +++)
Method Description	The cytotoxicity of Fab-SN38 was evaluated using the Cell Counting Kit-8 (CCK-8) assay. Cells (MDA-MB-231, Calu-3, NCI-N87 and SK-OV-3 cells) were seeded into clear-bottom 96-well plates (~3000 cells per well). After overnight culture, the medium was removed and the fresh medium containing SN38, Glu (SN38)-OH, Glu-SN38, trastuzumab, the Fab protein or the Fab-SN38 conjugate was added and incubated for 72 h at 37 °C in a CO2 incubator. Cell viability was measured using the CCK-8 reagent according to the protocol. Briefly, 15 uL of CCK-8 solution was added to the culture media. Two hours after incubation at 37 °C, the absorbance at a wavelength of 450 nm was measured by a microplate reader (TECAN, Switzerland) and then the IC50 value was profiled using the Graphpad Prism 8 software.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[11]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.47&#1770.29 nM	Positive HER2 expression (HER2+++/++)
Method Description	The cytotoxicity of Fab-SN38 was evaluated using the Cell Counting Kit-8 (CCK-8) assay. Cells (MDA-MB-231, Calu-3, NCI-N87 and SK-OV-3 cells) were seeded into clear-bottom 96-well plates (~3000 cells per well). After overnight culture, the medium was removed and the fresh medium containing SN38, Glu (SN38)-OH, Glu-SN38, trastuzumab, the Fab protein or the Fab-SN38 conjugate was added and incubated for 72 h at 37 °C in a CO2 incubator. Cell viability was measured using the CCK-8 reagent according to the protocol. Briefly, 15 uL of CCK-8 solution was added to the culture media. Two hours after incubation at 37 °C, the absorbance at a wavelength of 450 nm was measured by a microplate reader (TECAN, Switzerland) and then the IC50 value was profiled using the Graphpad Prism 8 software.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[11]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	The cytotoxicity of Fab-SN38 was evaluated using the Cell Counting Kit-8 (CCK-8) assay. Cells (MDA-MB-231, Calu-3, NCI-N87 and SK-OV-3 cells) were seeded into clear-bottom 96-well plates (~3000 cells per well). After overnight culture, the medium was removed and the fresh medium containing SN38, Glu (SN38)-OH, Glu-SN38, trastuzumab, the Fab protein or the Fab-SN38 conjugate was added and incubated for 72 h at 37 °C in a CO2 incubator. Cell viability was measured using the CCK-8 reagent according to the protocol. Briefly, 15 uL of CCK-8 solution was added to the culture media. Two hours after incubation at 37 °C, the absorbance at a wavelength of 450 nm was measured by a microplate reader (TECAN, Switzerland) and then the IC50 value was profiled using the Graphpad Prism 8 software.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.269 ng/mL	Positive PSMA expression (PSMA+++/++)
Method Description	ADCs (10x the final top concentration) was tested in LNCap cells for 3 days.
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395
Experiment 2 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.269 ng/mL	Positive PSMA expression (PSMA+++/++)
Method Description	ADCs (10x the final top concentration) was tested in C4-2B cells for 3 days.
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395

Experiment 1 Reporting the Activity Date of This ADC					[13]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.27 uM	High PD-L1 expression (PD-L1 +++)
Method Description	The cytotoxicity of SN38, IgG-NPLG-SN38 and aPDL1-NPLG-SN38 toward MC38 cells was evaluated using a CCK-8 assay. Specifically, the MC38 cells were seeded into 96-well plates (5 × 103 cells per well) and incubated overnight. SN38, IgG-NPLG-SN38 or aPDL1-NPLG-SN38 was then added at a range of concentrations (0.01-100 uM SN38) to each well and cultured for 72 h. CCK-8 reagent was then added to each well and incubated for 1 h, after which the plate was measured on a microplate reader at a wavelength of 450 nm. Cell viability was calculated from the ratio of optical density (OD) values of sample to control wells.    Click to Show/Hide
In Vitro Model	Mouse colon adenocarcinoma	MC38 cells		CVCL_B288

Experiment 1 Reporting the Activity Date of This ADC					[13]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 uM	High PD-L1 expression (PD-L1 +++)
Method Description	The cytotoxicity of SN38, IgG-NPLG-SN38 and aPDL1-NPLG-SN38 toward MC38 cells was evaluated using a CCK-8 assay. Specifically, the MC38 cells were seeded into 96-well plates (5 × 103 cells per well) and incubated overnight. SN38, IgG-NPLG-SN38 or aPDL1-NPLG-SN38 was then added at a range of concentrations (0.01-100 uM SN38) to each well and cultured for 72 h. CCK-8 reagent was then added to each well and incubated for 1 h, after which the plate was measured on a microplate reader at a wavelength of 450 nm. Cell viability was calculated from the ratio of optical density (OD) values of sample to control wells.    Click to Show/Hide
In Vitro Model	Mouse colon adenocarcinoma	MC38 cells		CVCL_B288

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ -20%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 2 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ -5%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Gastric adenocarcinoma	HS746T cells		CVCL_0333
Experiment 3 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 2%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 4 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 5%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186
Experiment 5 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 10%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 6 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 10%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186
Experiment 7 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 18%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186
Experiment 8 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 25%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Gastric adenocarcinoma	HS746T cells		CVCL_0333
Experiment 9 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 42%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 50%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Gastric adenocarcinoma	HS746T cells		CVCL_0333
Experiment 11 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 55%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Gastric adenocarcinoma	HS746T cells		CVCL_0333
Experiment 12 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 70%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 91 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ -5%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 2 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 5%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 3 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 16%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186
Experiment 4 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 17%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.xPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186
Experiment 5 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 20%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Gastric adenocarcinoma	HS746T cells		CVCL_0333
Experiment 6 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 25%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Gastric adenocarcinoma	HS746T cells		CVCL_0333
Experiment 7 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 38%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Gastric adenocarcinoma	HS746T cells		CVCL_0333
Experiment 8 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 38%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 40%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 10 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 55%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BxPC3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186
Experiment 11 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 65%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line HS746T cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Gastric adenocarcinoma	HS746T cells		CVCL_0333
Experiment 12 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 80%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 92 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	10-40 %	Positive HER2 expression (HER2+++/++)
Method Description	Her2-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3000 cells/well and treated with the compound 88 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 10%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 10%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 3 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 15%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 4 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 15%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung squamous cell carcinoma	NCI-H520 cells		CVCL_1566
Experiment 5 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 20%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung squamous cell carcinoma	NCI-H520 cells		CVCL_1566
Experiment 6 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 30%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 7 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 40%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 8 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 42%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung squamous cell carcinoma	NCI-H520 cells		CVCL_1566
Experiment 9 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 50%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 15%	Positive c-Met expression (c-Met+++/++)
Method Description	c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 5 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 25%	Positive c-Met expression (c-Met+++/++)
Method Description	c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 35%	Positive c-Met expression (c-Met+++/++)
Method Description	c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186
Experiment 4 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 45%	Positive c-Met expression (c-Met+++/++)
Method Description	c-Met-positive tumor cell line BxPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 93 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 20%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 90 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 45%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 90 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 65%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 90 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 20%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 2 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 22%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung squamous cell carcinoma	NCI-H520 cells		CVCL_1566
Experiment 3 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 25%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 4 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 35%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 5 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 40%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 6 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 42%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung squamous cell carcinoma	NCI-H520 cells		CVCL_1566
Experiment 7 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 65%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung squamous cell carcinoma	NCI-H520 cells		CVCL_1566
Experiment 8 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 70%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Lung large cell carcinoma	NCI-H661 cells		CVCL_1577
Experiment 9 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	≈ 75%	Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description	CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Cell growth inhibition ratio	60-80 %	Positive HER2 expression (HER2+++/++)
Method Description	Her2-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3000 cells/well and treated with the compound 86 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.34 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.38 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.41 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.46 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.46 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.5 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.51 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.73 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.81 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 13 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.83 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 14 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.84 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 15 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.16 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 16 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.16 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 17 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.5 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 18 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.66 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 19 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.72 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 20 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.77 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 21 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.84 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 22 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.21 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 23 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.29 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 24 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.45 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 25 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.88 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 26 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.52 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 27 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.68 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 28 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.22 nM	Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 29 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.5 nM	Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 30 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.68 nM	Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Adult B acute lymphoblastic leukemia	RS4;11 cells		CVCL_0093
Experiment 31 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.1 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 32 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.25 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 33 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.67 nM	Low CD22 expression (CD22+; Median fluorescence=16.0)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Childhood B acute lymphoblastic leukemia	697 cells		CVCL_0079
Experiment 34 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.7 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 35 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.92 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 36 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.2 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 37 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.65 nM	Low CD205 expression (CD205+; IHC 1+)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Burkitt lymphoma	MN-60 cells		CVCL_1421

Ref 1	Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012 Jan;11(1):224-34.
Ref 2	Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma. Haematologica. 2009 Oct;94(10):1456-9.
Ref 3	A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Mol Ther. 2022 Aug 3;30(8):2785-2799.
Ref 4	Antibody-Assisted Delivery of a Peptide-Drug Conjugate for Targeted Cancer Therapy. Mol Pharm. 2019 Jan 7;16(1):165-172. doi: 10.1021/acs.molpharmaceut.8b00924. Epub 2018 Dec 17.
Ref 5	Development of Novel Antibody-Camptothecin Conjugates. Mol Cancer Ther. 2021 Feb;20(2):329-339.
Ref 6	Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012 Jan;11(1):224-34. doi: 10.1158/1535-7163.MCT-11-0632. Epub 2011 Oct 28.
Ref 7	Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates. Drug Deliv. 2021 Dec;28(1):2603-2617.
Ref 8	Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity. Biomed Pharmacother. 2023 Jan;157:114047.
Ref 9	Ph-dependent Anti-sulfated glycosaminoglycan antibody and antibody-drug conjugate
Ref 10	Conjugates and antibody-drug conjugates prepared therefrom
Ref 11	A single-chain fab derived drug conjugate for HER2 specific delivery
Ref 12	Anti-PSMA antibody-drug conjugates and their preparation methods and applications
Ref 13	Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy
Ref 14	PEGylated antibody hydroxyl-bearing drug conjugates